Standing Blood Pressure and Risk of Falls, Syncope, Coronary Heart Disease, and Mortality.
Standing Blood Pressure and Risk of Falls, Syncope, Coronary Heart Disease, and Mortality.
复制标题
站立血压与跌倒、晕厥、冠心病和死亡的风险。
DOI:
10.1093/ajh/hpad064
复制
发表时间:
2023
影响因子:
3.2
通讯作者:
Juraschek,StephenP
中科院分区:
文献类型:
--
作者:
Kondo,JordanK;Earle,WilliamB;Turkson-Ocran,Ruth-AlmaN;Ngo,LongH;Cluett,JenniferL;Lipsitz,LewisA;Daya,NatalieR;Selvin,Elizabeth;Lutsey,PamelaL;Coresh,Josef;Windham,BeverlyGwen;Kendrick,KarlaN;Juraschek,StephenP
BACKGROUNDACC/AHA guidelines caution against the use of antihypertensive therapy in the setting of low standing systolic BP (SBP) < 110 mm Hg due to unclear benefits.METHODSThe Atherosclerosis Risk in Communities (ARIC) Study measured supine and standing SBP in adults aged 45–64 years between 1987 and 1989. We used Cox regression to evaluate the associations of low standing SBP (<110 mm Hg) with risk of falls, syncope, coronary heart disease (CHD), and mortality through December 31, 2019. Falls and syncope were ascertained by hospitalization and outpatient claims; CHD events were adjudicated. Associations were examined overall and in strata of hypertension stage, 10-year atherosclerotic cardiovascular disease (ASCVD) risk, age, and sex.RESULTSAmong 12,467 adults followed a median of 24 years (mean age at enrollment 54.1 ± 5.8 years, 55% women, 26% Black adults), 3,000 (24%) had a standing SBP < 110 mm Hg. A standing SBP < 110 mm Hg compared to standing SBP ≥ 110 mm Hg was not significantly associated with falls or syncope, and was associated with a lower risk of CHD events and mortality with HRs of 1.02 (95% CI 0.94, 1.11), 1.02 (0.93, 1.11), 0.88 (0.80, 0.97), and 0.91 (0.86, 0.97), respectively. There were no clinically meaningful differences when stratified by hypertension stage, 10-year ASCVD risk, age, and sex.CONCLUSIONSIn this community-based population, low standing SBP was common and not significantly associated with falls or syncope, but was associated with a lower risk of CHD and mortality. These findings do not support screening for low standing BP as a risk factor for adverse events.